Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pyxis Oncology ( (PYXS) ) has provided an announcement.
On December 18, 2025, Pyxis Oncology reported positive preliminary Phase 1 data for its first-in-concept antibody-drug conjugate MICVO in recurrent/metastatic head and neck squamous cell carcinoma, showing a 46% confirmed overall response rate and 92% disease control rate as monotherapy in heavily pretreated second-line and later patients, along with generally manageable safety issues that the company aims to further address by shifting to adjusted ideal bodyweight dosing. In a separate Phase 1/2 study, MICVO combined with Merck’s checkpoint inhibitor KEYTRUDA delivered a 71% confirmed response rate and 100% disease control in a small HPV-positive cohort with no Grade 3 or 4 payload-related toxicities or treatment discontinuations, while Pyxis also strengthened its balance sheet by selling royalty rights to Enzeshu for $11 million, leaving the company funded through key data milestones and into the fourth quarter of 2026 as it advances toward pivotal studies in this high-need oncology indication.
The most recent analyst rating on (PYXS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Pyxis Oncology stock, see the PYXS Stock Forecast page.
Spark’s Take on PYXS Stock
According to Spark, TipRanks’ AI Analyst, PYXS is a Neutral.
Pyxis Oncology’s score reflects ongoing financial challenges with significant cash burn and unprofitability. While there are positive developments with the strategic focus on its lead candidate, technical indicators suggest caution. Valuation remains unattractive due to negative earnings. The company’s future hinges on successful execution of its strategic initiatives.
To see Spark’s full report on PYXS stock, click here.
More about Pyxis Oncology
Pyxis Oncology, Inc., based in Boston and listed on Nasdaq, is a clinical-stage biotechnology company developing next-generation cancer therapeutics, with a particular focus on antibody-drug conjugates such as micvotabart pelidotin (MICVO) for difficult-to-treat solid tumors including recurrent/metastatic head and neck squamous cell carcinoma.
Average Trading Volume: 736,205
Technical Sentiment Signal: Buy
Current Market Cap: $249.1M
For detailed information about PYXS stock, go to TipRanks’ Stock Analysis page.